Highlights

  • IPX shares traded at A$4.445, up A$0.345 (+8.41%) during the May 1, 2026 session, with Volume reaching 3.14 million shares
  • March 2026 quarterly powder production reached ~4.2 metric tons, equivalent to approximately 50 tpa annualised, with a target of ~200 tpa by end-CY2026
  • US$48.2 million cash on hand plus US$42.1 million in remaining obligated reimbursable US Government funding at quarter-end

 

Shares in IperionX Limited (ASX:IPX) were among the standout performers on the ASX on May 1, 2026, trading at A$4.445 — a gain of A$0.345 or 8.41% during the session. Volume of 3.14 million shares significantly exceeded typical trading activity, reflecting broad investor interest following the company's March 2026 Quarterly Report released on April 27. With a Market Capitalisation of approximately A$1.39 billion, IperionX has cemented its position as a notable mid-cap presence within the Australian critical materials and advanced Manufacturing space.

The share price movement on May 1 came in the wake of a Quarterly Report that outlined accelerating operational progress at the company's Virginia Manufacturing Facility. Investors appear to have responded positively to the combination of production ramp-up milestones, growing US Government financial support, and the company's disciplined Cash Management, which collectively paint a picture of a Business approaching a meaningful commercial inflection.

Operations: Transitioning From Commissioning to Continuous Production

Perhaps the most significant operational development disclosed in IperionX's March 2026 Quarterly Report was the transition of its Virginia operations to a 24/7 production schedule. This shift from commissioning to continuous operations represents a structural change in the company's operational tempo and is widely regarded as an important de-risking milestone for Manufacturing businesses at this stage of development.

All HAMR™ powder production systems have now been commissioned and are in the ramp-up phase. During March alone, production reached approximately 4.2 metric tons of titanium powder — equivalent to an annualised run rate of roughly 50 tpa. While this remains considerably below the company's target of approximately 200 tpa by end-CY2026, management has indicated that throughput is expected to build as the product mix shifts toward higher-Volume angular powders and powder-to-part Manufacturing. The early-stage nature of the ramp was acknowledged by the company, and the trajectory of improvement from one quarter to the next has been a key point of focus for the market.

On the Manufacturing side, IperionX made progress in scaling its powder metallurgy operations. A 100-ton uniaxial press has been optimised, and the company commissioned a cold isostatic press for larger-format titanium components. An advanced six-axis 300-ton SACMI powder metallurgy press was also installed during the quarter, capable of producing more complex part geometries and supporting higher-rate production. Commissioning of this press is planned for the June quarter, which is expected to broaden the range of titanium components IperionX can offer customers.

Next-Generation Technology: The GenX™ Platform

A development attracting considerable attention from analysts is the progress of GenX™ — IperionX's next-generation continuous HAMR™ platform. Unlike current batch-processing systems, GenX™ is designed to deliver a step-change in Capital efficiency, operating cost reduction, and throughput capacity. The company advanced development of this platform during the March quarter, though specific deployment timelines have not yet been publicly confirmed.

GenX™ is strategically important because it underpins the long-term Economics of IperionX's Business model. If successful, it would substantially reduce the cost of producing titanium powder at scale, opening up larger markets where price sensitivity is a key purchasing Factor. The development of this platform, alongside ongoing investments in additive Manufacturing capability — including the operation and retrofit of additional binder jet systems — demonstrates the company's broader ambitions beyond initial defense and aerospace markets.

Customer Traction and Commercial Strategy

IperionX's go-to-market approach continues to be tiered, with near-term focus on higher-value engineered products where its competitive advantages — including superior material yields, faster design iteration, and rapid prototyping — are most pronounced. During the March quarter, production activity was concentrated on prototype production, product development, qualification testing, and low-rate initial production across defense, automotive, consumer electronics, and industrial applications.

Customer engagement across aerospace and defense markets increased materially, supported by heightened focus on titanium Supply-chain resilience, US onshoring of advanced component Manufacturing, and reduced dependence on imported primary titanium. Qualification and test work for spherical titanium powders in the consumer electronics sector also accelerated, a market the company has identified as a significant potential opportunity for both powder sales and manufactured component Revenue.

Customer receipts remain at the early inflection point of the commercial adoption curve, consistent with the prototype and qualification-focused activity during the quarter. Management acknowledged that as qualification milestones are achieved and purchase-order schedules become more defined, customer receipts should build — subject to program timing and delivery schedules.

US Government Support and the 1,400 tpa Expansion Program

A differentiating feature of IperionX's position is the depth of its engagement with the US Government. The company's 1,400 tpa titanium expansion program continued to progress during the quarter, including the full obligation of a US$47.1 million Industrial Base Analysis and Sustainment (IBAS) award aimed at building a fully integrated domestic titanium mineral-to-metal Supply chain. The US Government also transferred approximately 290 metric tons of titanium scrap to IperionX at no cost — equivalent to roughly 1.5 years of titanium feedstock — further underpinning operational continuity.

An SBIR Phase III IDIQ contract worth up to US$99 million has also been secured, with additional task orders progressing. These government programs not only provide financial support but validate IperionX's strategic importance within the US critical minerals and defense Supply chain ecosystem — a Factor that continues to attract institutional investor interest both in Australia and the United States.

Financial Position and FY2026 Cash Guidance

IperionX ended the March 2026 quarter with US$48.2 million in cash. The company noted that the quarter included approximately US$4.8 million of non-run-rate and timing-related cash items. Beyond the cash balance, US$42.1 million of remaining obligated reimbursable US Government funding was outstanding at March 31, 2026, including US$3.5 million of eligible expenditure already incurred but not yet reimbursed.

Based on current operating plans, planned Capital expenditure, and expected US Government reimbursement timing, IperionX expects to exit FY2026 with cash in the range of US$36 million to US$40 million. This guidance provides investors with reasonable visibility into the near-term funding position, and the significant US Government reimbursable funding pipeline reduces the near-term risk of a Capital raise that could otherwise weigh on the share price.

Titan Critical Minerals Project

The Titan Critical Minerals Project, a fully permitted US project, continues to advance through the Definitive Feasibility Study (DFS) process, with completion targeted for mid-2026. Titan holds significant strategic value given its exposure to titanium, rare earths, and zircon — including the heavy rare earths dysprosium, terbium, and yttrium. IperionX is in discussions with the US Government regarding potential funding pathways to accelerate Titan's development following DFS completion, a development that could serve as a meaningful catalyst for the stock when formalised.

Conclusion

IperionX's May 1 share price gain of 8.41% to A$4.445 reflects investor recognition of meaningful operational progress. The transition to 24/7 production, advancement of the GenX™ platform, deepening US Government engagement, and a well-supported cash position all contribute to a narrative of a company progressing deliberately through a critical commercialisation phase. With a Market Capitalisation of A$1.39 billion and significant government-backed funding runway, IperionX is increasingly viewed as one of the more credible domestic US titanium Manufacturing stories. The pace of customer qualification milestones and powder production throughput over the next two quarters will be closely watched by the market.